Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens

Diagnostic Cytopathology

Volumn 37, Issue 12, 2009, Pages 885-890

  Kimura, Noriko ^a   Dota, Kimiko ^a   Araya, Yoshikazu ^a   Ishidate, Takuzo ^a   Ishizaka, Masanori ^a  

^a Hakodate Hospital   (Japan)

Author keywords

Mesothelioma; Reactive mesothelial cells; Scoring system

Indexed keywords

CALRETININ; PICIBANIL; PODOPLANIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CELL SIZE; CLINICAL ARTICLE; CYTOLOGY; CYTOPLASM; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; METASTASIS; NUCLEOLUS; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; SCORING SYSTEM; STOMACH ADENOCARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 72149123154     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21128     Document Type: Article

References (17)

1. Grondin SC, Sugarbaker DJ. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 1999;116 (6 Suppl): 450S-454S.
2. Pagan V, Ceron L, Paccagnella A, Pizzi G. Five-year prospective results of trimodality treatment for malignant pleural mesothelioma. J Cardiovasc Surg 2006;47:595-601. (Pubitemid 44696791)
3. Okada M, Mimura T, Ohbayashi C, Sakuma T, Soejima T, Tsubota N. Radical surgery for malignant pleural mesothelioma: results and prognosis. ICVTS 2008;7:102-106.
4. Iyoda A, Yusa T, Kadoyama C, et al. Diffuse malignant pleural mesothelioma: A multi-institutional clinicopathological study. Surg Today 2008;38:993-998.
5. Pomjanski N, Grote HJ, Sander O, Heikaus S, Muller K-M, Bocking A. Early cytological diagnosis of diffuse malignant mesothelioma of the peritoneum: A case report. Diagn Cytopathol 2008;36:120-123.
6. Churg A, Cagle PT, Roggli VL. Cytology of the serosal surfaces. In: Churg A, Cagle PT, Roggli VL, editors. AFIP Atlas of tumor pathology series 4. Tumors of the serosal membranes. Washington, DC, AFIP; 2006. p 11-32.
7. Whitaker D. The cytology of malignant mesothelioma. Cytopathology 2000;11:139-151.
8. Stevens MW, Leong AS-Y, Fazzalari NL, Dowling KD, Henderson DW. Cytopathology of malignant mesothelioma: A stepwise logistic regression analysis. Diagn Cytopathol 1992;8:333-341.
9. Cakir E, Demirag F, Aydin M, Unsal E. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis. Diagn Cytopathol 2009;37:4-10.
10. Patel NP, Taylor CA, Levine EA, Trupiano JK, Geisinger KR. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens. Examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol 2007; 128:414-422.
11. Fassina A, Fedeli U, Corrandin M, Da Fre M, Fabbris L. Accuracy and reproducibility of pleural effusion cytology. Legal Med 2008; 10:20-25. (Pubitemid 350167005)
12. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int 2005;55:83-86.
13. Abe K, Takashima K, Igarashi T, Ootomo K, Kimura N. Immunocytochemical study of podoplanin for distinguishing reactive mesothelial cells from adenocarcinoma in body cavity fluids. J Jpn Soc Clin Cytol 2006;45:1-5.
14. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmenbrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913-921. (Pubitemid 40315647)
15. Bhalla R, Siddiqui MT, Mandich D, et al. Diagnostic utility of D2- 40 and podoplanin in effusion cell blocks. Diagn Cytopathol 2007; 35:342-347. (Pubitemid 46835024)
16. Maeda S, Katayama H, Iwase H, Naito Z. A case report on pleural mesothelioma. Effective application of the cell block method to body cavity fluid cytological analysis. J Jpn Soc Clin Cytol 2007; 46:386-390.
17. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol 2007;36: 20-25.